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Abstract p27Klpl is an inhibitor of multiple cyclin-dependent 
kinases (cdk), and can arrest the cell-cycle progression by 
inhibiting the phosphorylation of the retinoblastoraa gene family 
products. Tumor formation in p27Klpl knockout mice clearly 
shows that p27Klpl plays an important role in inhibiting tumor 
formation and progression. To investigate the mechanism of 
transcriptional p27Klpl gene expression, we isolated the genomic 
DNA fragment of the 5' flanking region of the human p27Klpl 
gene and characterized its promoter region. The human p27Klpl 
promoter is TATA-less, and the sequence is highly homologous 
to the murine p27Klpl promoter sequence. In the promoter assay, 
deletion from —774 to —435 relative to the initiating codon 
resulted in a 15-20-fold reduction of the p27Klpl promoter 
activity, suggesting that the elements for basal promoter activity 
exist in this highly conserved 340 bp region, where putative CTF 
and ATF sites are conserved. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
In the eukaryotic cell cycle, several positive and negative 
factors regulate the cell-cycle progression. Among the positive 
factors, the key players are a family of protein kinases each of 
which comprises a regulatory subunit, or cyclin, and a cata-
lytic subunit, termed a cyclin-dependent kinase (cdk). A num-
ber of reports suggest that cyclin D-cdk4, cyclin D-cdk6 and 
cyclin E-cdk2 play important roles in promoting the transition 
from the Gl-phase to the S-phase by the phosphorylation of 
the retinoblastoma protein (pRB). One further level of control 
has recently become apparent, namely, the expression of cdk 
inhibitors [1]. Two families of cdk inhibitors have already 
been identified in mammalian cells, with different modes of 
action. One group, comprised of related proteins known as 
p21c lp l , p27klpl and p57klp2, appears to function as broad spe-
cificity inhibitors of cyclin/cdk complexes [2-5]. The second 
family of cdk inhibitors is also called INK4 family proteins. 
The four members of this family, designated pl5, pl6, pl8 
and pi9, bind directly to cdk4 and cdk6 and are therefore 
specific inhibitors of the cyclin D-dependent kinases [6-8]. 
Although the precise roles of p27Klpl are far from clear, its 
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level declines as cells are stimulated to enter the cycle, and 
increases when cells are arrested by transforming growth fac-
tor or by contact inhibition [9]. p27Klpl was cloned as a bind-
ing protein with cyclin E-cdk2 [3] or cyclin D-cdk4 [4]. p27Klpl 
inhibits the activity of most cyclin-cdk complexes, and in 
addition, is capable of inhibiting the phosphorylation of cy-
clin-cdk complexes by CAK (cdk-activating kinase) [10]. 
p27Klpl therefore functions as a negative regulator of Gl/S 
progression. 
Tumor-specific mutations of the p27Klpl gene are rare [11], 
whereas several cell cycle regulators such as pl6, p53 and RB 
are frequently mutated in several cancers and have been 
shown to be tumor-suppressor genes. However, p27Klpl -defi-
cient mice were observed to have increased body size, multiple 
organ hyperplasia, retinal dysplasia, and the formation of the 
pituitary tumors [12-14], which is in part similar to the case of 
the RB heterozygous knockout mice [15]. In addition, cohort 
studies of breast and colorectal carcinoma patients showed 
that a lower expression of the p27Klpl protein correlated 
with poorer survival [16-18]. These results clearly indicate 
that p27Klpl plays an important role in inhibiting tumor for-
mation and tumor progression. The expression of p27Klpl has 
been shown to be controlled by a post-translational mecha-
nism [19,20]. However, recent reports showed that p27Klpl 
mRNA is induced by vitamin D3 in U937 cells [21] and by 
neuronal differentiation [22], suggesting that transcriptional 
regulation of the p27Klpl gene might be also important in 
cellular differentiation. In the present study, to investigate 
the mechanism of the transcriptional regulation of the 
p27Klpl gene, we cloned the 5' flanking region of the human 
p27Klpl gene and analyzed its promoter region. 
2. Materials and methods 
2.1. Cell culture 
The human osteosarcoma cell lines Saos2 and U20S (kind gifts 
from Dr. R. Takahashi, Kyoto University and from Dr. E. Hara, 
Kyoto Prefectural University, respectively) and the human cervical 
carcinoma cell line C33A (purchased from the American Type Culture 
Collection, Rockville, MD) were maintained in Dulbecco's modified 
Eagle's medium with 10% fetal bovine serum and incubated at 37°C in 
a humidified atmosphere of 5% CO2 in air. In the U20S cells, the p53 
and RB genes are intact [23], and in the Saos2 [23,24] and C33A [25] 
cells, both the p53 and RB genes are mutated. 
2.2. Cloning of the human p27K'vl promoter fragment 
A part of the human p27Klpl cDNA containing exon 1 was ob-
tained from the human p27Klpl cDNA inserted in the plasmid pBlue-
script SK-p27FL (a kind gift of Dr. J. Massague, Memorial Sloan-
Kettering Cancer Center, USA) by digestion with EcoRl and Pstl, 
and was used as a probe to screen a human leukocyte genomic library. 
Using this probe, about 106 phage plaques of a human leukocyte 
genomic library in the EMBL3 SP6/T7 phage vector (Clontech, Palo 
Alto, CA) was screened to obtain the genomic DNA fragments con-
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CCACGGTGCTCAAGCCCACACTGAGAGAGAAATTTCCAGCTGCAAAAGGGAGAAGAGAAACG 
-1600 
CTGGAATACTAGTATCGGACGTTAGGACATGGTTGTGGTGTTTTAAAAATCATTTCATCATC 
TGGAGTTTGACCCCGAGGGGAGTATTTTCACCCTTCAGCCCTCTGAAAGCATTCACTAGCAT 
-1500 
CTGAATATTGTTCTGAGTTTGTTGGAGCAGTGAAATCTGGTGAGAGAGAAGGGTGGAGGAAG 
PEA3
-1400~ 
GAAGGAGCTGTTGTATTTGGCGGCTGGACTCAGGTAGAGGAAACTGCTACAATCCCGGGAAA 
PEA3 
GAACAGAAAAGTAGAAAGGGACGAGTTCCCACACGCAGCCAATGTCCATGGCCTTAACTGTG 
-1300 CTF Myb 
CTTGGGAAGGAAGATCCTGGGCCAGGGGTGTACCCTCGTTTTTCAAAAACTAAACGTGTCTG 
PEA3 
AGACAGCTACAAAGTTTATTAAGGGACTTGAGAGACTAGAGTTTTTTGTTTTTTTTTTTTAA 
-1200 
TCTTGAGTTCCTTTCTTATTTTCATTGAGGGAGAGCTTGAGTTCATGATAAGTGCCGCGTCT 
-1100 
ACTCCTGGCTAATTTCTAAAAGAAAGACGTTCGCTTTGGCTTCTTCCCTAGGCCCCCAGCCT 
CCCCAGGGATGGCAGAAACTTCTGGGTTAAGGCTGAGCGAACCATTGCCCACTGCCTCCACC 
-1000 
AGCCCCCAGCAAAGGCACGCCGGCGGGGGGGCGCCCAGCCCCCCCAGCAAACGCTCCGCGGC 
CTCCCCCGCAGACCACGAGGTGGGGGCCGCTGGGGAGGGCCGAGCTGGGGGCAGCTCGCCAC 
-900 AP2 
CCCGGCTCCTAGCGAGCTGCCGGCGACCTTCGCGGTCCTCTGGTCCAGGTCGCGGCTTCCCG 
-800 
GGAGAGGAGCGGGAGGGAGGTCGGGGCTTAGGCGCCGCTGCGAACCCGCCAACGCAGCGCCG 
,-^ - p27Apa I AP2 
GGCCCCGAACCTCAGGCCCCGCCCCAGGTTCCCGGCCGTTTGGCTAGTTTGTTTGTCTTAAT 
-700 Sp1 AP2 
TTTAATTTCTCCGAGGCCAGCCAGAGCAGGTTTGTTGGCAGCAGTACCCCTCCAGCAGTCAC 
-600 
GCGACCAGCCAATCTCCCGGCGGCGCTCGGGGAGGCGGCGCGCTCGGGAACGAGGGGAGGTG 
CTF 
GCGGAACCGCGCCGGGGCCACCTTAAGGCCGCGCTCGCCAGCCTCGGCGGGGCGGCTCCCGC 
-500 Sp1 Sp1 
CGCCGCAACCAATGGATCTCCTCCTCTGTTTAAATAGACTCGCCGTGTCAATCATTTTCTTC 
CTF r^. P27MB-43S 
TTCGTCAGCCTCCCTTCCACCGCCATATTGGGCCACTAAAAAAAGGGGGCTCGTCTTTTCGG 
ATF. 400 
GGTGTTTTTCTCCCCCTCCCCTGTCCCCGCTTGCTCACGGCTCTGCGACTCCGACGCCGGCA 
AP2
 r^p27SacII .300 
AGGTTTGGAGAGCGGCTGGGTTCGCGGGACCGCGGGCTTGCACCCGCCCAGACTCGGACGGG 
PEBP2 AP2 Sp1 
CTTTGCCACCCTCTCCGCTTGCCTGGTCCCCTCTCCTCTCCGCCCTCCCGCTCGCCAGTCCA 
-200 Spl AP2 ,-^p27BssHn 
TTTGATCAGCGGAGACTCGGCGGCCGGGCCGGGGCTTCCCCGCAGCCCCTGCGCGCTCCTAG 
T NF/cB -100 
AGCTCGGGCCGTGGCTCGTCGGGGTCTGTGTCTTTTGGCTCCGAGGGCAGTCGCTGGGCTTC 
CGAGAGGGGGTTCGGGCCGCGTAGGGGCGCTTTGTTTTGTTCGGTTTTGTTTTTTTGAGAGT 
1 
GCGAGAGAGGCGGTCGTGCAGACCCGGGAGAAAdATGl 
Fig. 1. Nucleotide sequence of the 5' flanking region of the human p27Klpl gene. The transcriptional start site of the human p27Klpl gene was 
determined by primer extension and is indicated by the arrowhead (T) . The consensus sites of various transcriptional factors are indicated and 
underlined. The nucleotide number was counted from the translational start site. The arrows indicate the 5' end of the deletion mutants of 
p27Klpl promoters shown in Fig. 3. 
taining the 5' region of the human p27Klpl gene. Hybridization was 
performed in a buffer containing 5XSSC, 50% formamide, 1% SDS, 
5xDenhards solution, and 0.1 |ig/ul denatured and sonicated fish 
sperm DNA at 42°C for over 16 h. The positive phage plaques 
were expanded and the DNA was purified. The genomic DNA frag-
ments were digested with the appropriate enzymes and analyzed by 
Southern blotting. 
2.3. Plasmid preparation 
An approximately 4.8 kb Xho\ fragment derived from the positive 
phage DNA was subcloned into pBluescript SK+ (Stratagene, La 
Jolla, CA). This construct was used for sequencing, and an approx-
imately 3.5 kb fragment between —3568 and —12 from the start site of 
translation of the human p27Klpl gene was subcloned into the lucifer-
ase reporter plasmid pGVB2 (Nippon Gene, Tokyo, Japan). This 
human p27Klpl-luciferase fusion plasmid was termed p27PF. To gen-
erate the deletion mutants of p27PF, p27PF was digested separately 
with Kpnl, Apal, SacII and itasHII. These enzyme sites were blunted 
with Klenow or T4 DNA polymerase and then self-ligated. These 
plasmids were termed p27KpnI, p27ApaI, p27SacII and p27BssHII, 
respectively. Another deletion mutant termed p27MB-435 was gener-
ated using a Mungbeans-Exonuclease III system, the Kilo-sequence 
Deletion Kit (Takara, Tokyo, Japan). The series of all of the gener-
ated constructs were confirmed by sequencing. 
2.4. DNA sequencing and primer extension analysis 
The sequence was determined by the dideoxynucleotide chain ter-
mination method using a USB sequenase version 2.0 DNA sequencing 
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kit (Amersham, Buckinghamshire, UK). The primers used for se-
quencing were T3, T7 and synthetic oligonucleotides derived from 
the genomic DNA sequence. To determine the transcriptional start 
site, two 20-bp oligonucleotides, 0-128 (5'-CCCAGC-
GACTGCCCTCGGAG-3'), and 0-234 (5'-CCCTCTCGGAAGCC-
CAGCGA-3'), complementary to the regions from —120 to —101 
and from —108 to —89, respectively, were end-labeled using 
[y-32P]ATP and T4 polynucleotide kinase (Toyobo, Osaka, Japan). 
This extension primer was hybridized to 20 (ig of total RNA isolated 
from human osteosarcoma MG63 and Saos2 cells at 42°C. The an-
nealed primers were extended with 200 U of Superscript II reverse 
transcriptase (Gibco BRL, Gaithersburg, MD) for 50 min at 42°C. 
The resultant products were analyzed on a 6% polyacrylamide dena-
tured gel in parallel with a sequencing reaction generated with the 
same extension primer. 
2.5. Transient transfection 
C33A cells (5 X 105 cells) and U20S cells (3 X105 cells) were seeded 
into 6-cm-diameter tissue culture dishes. After 24 h, 2 ug of p27PF 
and 1 itg of RSV|3-gal, containing the (3-galactosidase gene under the 
control of the Rous sarcoma virus promoter (for normalizing the 
transfection efficiency) were co-transfected into cells using the calcium 
phosphate co-precipitation method [26], and the luciferase activity was 
measured after 48 h. 
2.6. Luciferase assay 
The luciferase activity of each cell lysate was measured as described 
previously [27], and was normalized by P-galactosidase activities in the 
cell lysates. All the transfection assays were carried out in triplicate. 
Each experiment was repeated at least twice. 
3. Results and discussion 
3.1. Molecular cloning of human genomic DNA fragment 
containing the p27Ktpl promoter 
To investigate the mechanism of the transcriptional regula-
tion of the p27Klpl gene, we cloned a genomic DNA fragment 
containing the human p27Klpl promoter region. A part of the 
human p27Klpl cDNA fragment containing exon 1 was ob-
tained by digestion with EcoRl and Pstl from the human 
p27Klpl cDNA-inserted plasmid SK-p27FL, and was used to 
screen a human leukocyte genomic library. Using this probe, 
about 106 phage plaques of a human leukocyte genomic li-
brary was screened to obtain the genomic DNA fragments 
containing the 5' flanking region of the human p27Klpl gene. 
One positive clone was identified and the phage DNA was 
purified. The positive phage DNA was digested with several 
restriction enzymes and analyzed by Southern blotting using 
the same probe. This fragment contained the 5' flanking re-
gion, exon 1 and intron 1 of the human p27Klpl gene (data not 
shown). 
3.2. Sequence analysis of the human p27K'pl promoter 
A 4.8 kb fragment digested by Xhol was subcloned into 
pBluescript SK+ and sequenced. This fragment contained 
the 5' flanking region, the first exon and the first intron. 
The sequence of the 5' untranslated region of the genomic 
DNA fragment was identical to the sequence of the human 
p27Klpl cDNA probe. The computer search using GENETYX 
software (Software Development Co, Tokyo, Japan) for po-
tential regulatory elements in the promoter region revealed 
that there could be multiple transcription factor binding sites 
such as Spl, PEA3, CTF, Myb, PEBP2, AP2, N F K B and 
ATF (Fig. 1) which might transcriptionally regulate p27Klpl 
gene expression. Analysis of the region surrounding the tran-
scriptional start site failed to reveal the presence of a TATA 
box. 
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Fig. 2. Primer extension mapping of the human p27Klpl gene. Primer extension was performed as described in Section 2. Extension products 
from primer 0-128 are shown using total RNA from MG63 and Saos2 cells as the template. In this figure, the antisense sequence ladder is 
shown. The arrow indicates the C-residue (G-residue in sense strand) as a putative transcriptional start site. S; sense strand, AS; antisense 
strand. 
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Fig. 3. Deletion mutants of the human p27Kipl promoter-luciferase 
constructs. The human full-size p27Kipl promoter-luciferase con-
struct, p27PF, was generated by subcloning the DNA fragment 
from the Xhol site (-3568) to Smal site (-12), in front of the luci-
ferase reporter gene in pGVB2. The 5' deletion constructs were gen-
erated by using restriction enzyme sites or the Mungbeans-Exonu-
clease III system. 
3.3. Transcriptional start site of the human p27K'pl promoter 
To identify the transcriptional start site, a primer extension 
analysis was performed. We used two distinct primers anneal-
ing to the different sequence of the first exon. As templates, 
two kinds of mRNA of human osteosarcoma MG63 and 
Saos2 cells were used. The two primers extended to the 
same G-residue at the position —153 from the translational 
start site reproducibly in mRNA from these two cell lines 
(Fig. 2), where we suspect the major transcriptional start 
site is. In the upstream region, there could be two more tran-
scriptional start sites at —225 and —247 (data not shown). 
3.4. Promoter activity and deletion analysis of the human 
p27Ktpl promoter 
To determine the core element for the human p27Klpl pro-
moter activity, several deletion mutants were generated by 
using restriction enzyme sites and also by the Mungbeans-
Exonuclease III system. A series of the 5' deletion constructs 
was subcloned into the luciferase reporter plasmid pGVB2 
(Fig. 3) and transiently transfected into C33A and Saos2 cells. 
The RSV|3-galactosidase plasmid was used as an internal con-
trol. The promoter activities of the full-size human p27Klpl 
promoter construct, p27PF, and the deleted constructs of 
p27KpnI and p27ApaI were not significantly different. How-
ever, the promoter activity of the p27MB-435 construct was 
markedly decreased, by about 15-20-fold compared to that of 
the p27ApaI construct in the C33A and Saos2 cells (Fig. 4a,b) 
and U20S cells (data not shown). This decrease in promoter 
activity suggests that the essential transcriptional factor bind-
ing sites or enhancer sites for the human p27Klpl promoter 
activity could exist in this region. 
3.5. Comparison of the human and mouse p27Ktpl promoter 
sequences 
The comparison of the human and murine p27Klpl pro-
moters by a computer analysis using GENETYX software 
revealed that the sequence of the human p27Klpl promoter is 
highly homologous to the murine p27Klpl promoter (Fig. 5) 
[28]. The sequence of the region between —774 and —435, 
which includes the region for basal promoter activity (Fig. 
4a,b), matches the murine sequence by 85%, suggesting that 
the consensus and essential transcription factors could act on 
this region. Putative transcriptional factor binding sites in this 
region are three consensus Spl sites, an AP2 site, two CTF 
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Fig. 4. Basal promoter activities of the human p27Klpl promoter 
constructs. Transfection was performed as described in Section 2 
with the various 5'-deleted human p27Klpl promoter-luciferase con-
structs using C33A (a) and Saos2 cells (b). The luciferase activity 
was normalized by p-galactosidase activity driven by co-transfected 
RSV-gal. 
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sic CCTAGATCCCCGGGTCCCTGCCTGGCCGCCGCGCTGGCCCCTCCCCAGCTCTCCGGCCGT mo 
* * * ***** W * * * * ****** ****** * ******** 
AC-GCAGCGCCGGG CcfccGAACCTCAGGCCCCGCCCCAGGTTCCCGGCCGT hu 
1
 Spl ^ 2 
TTCGTGIAGTTTGTTTGTCTTATTTTTAATTTCTCAGGGGCCAGCCAGAGCAGGTTTGTTG mo 
** * *************** ************ * *********************** 
TTGGCTAGTTTGTTTCTCTTAATTTTAATTTCTCCGAGGCCAGCCAGAGCAGGTTTGTTG hu 
GCAGTCGTACACCTCKGAGTAGTCACGCGACCAGCCAATGTCCTGGCGGCGCTACGGGGA mo 
**** **** ***** ** ******************* *** ********* ****** 
GCAGCAGTACCCCTCC-AGCAGTCACGCGACCAGCCAATCTCCCGGCGGCGCT-CGGGGA hu 
CTF 
GGCGGC-CGCTCGGGAGCCAGAGGCGGCGGCGG—CC CGGGGCCACCTTAAGAGCG mo 
****** ********* * ** ** ** ***** ** *************** ** 
GGCGGCGCGCTCGGGAACGAGGGGAGGTGGCGGAACCGCGCCGGGGCCACCFTAAGGCCG hu 
CG-TCG-CAGCCT GGGGAGGCTCCCGGCACCGAGACCAATGGAGCTCCTCCTCTGT mo 
** *** ****** **** ******** * *** ********* *********** 
CGCTCGCCAGCCTCGGCGGGGCGGCTCCCGCCGCCGCAACCAATGGATCTCCTCCTCTG- hu 
Spl Spl CTF 
TTTAAATAGACTTGCAGTGTCAATCATCTTCTTCTTCGTCAGCCTCCCTTCCACCGCCAT mo 
************ ** *********** ******************************** 
TTTAAATAGACTCGCCGTGTCAATCATTTTCTTCTTCGTCAGCETCCCTTCCACCGCCAT hu 
A T F _ _ 
ATTGGGCAKCTAAAAAAGGAGGGGGGCTGCTTT-TGGGTGTTTTCCCCCTCGTCCCTTGT mo" 
******* I********* * *** * *** ********* * ** * **** *** 
ATTGGGCdACTAAAAAAAGGGGGCTCGTCTTTTCGGGGTGTTTOTCTCCCCCTCCCCTGT hu 
' AP2 
-CCCACTCACTCGCGGCTCCGAGACT-GGGCGGCGGCAAGGTTTGGAGAGGGGCT-GGTT mo 
*** ** *** ****** * **** * ** ***************** **** **** 
CCCCGCTTGCTCACGGCTCTGCGACTCCGACGCCGGCAAGGT1TGGAGAGCGGCTGGGTT hu 
CGCGGGA-CACACGCTCGCCCCAGCCTACGCTCCGAC—TGTTTGCCA-CCT—CCTCCT mo 
******* * * *** ** ** *** * *** *** ******* *** ** * * 
CGCGGGACCGCGGGCTTGCACCCGCCCAGACTCGGACGGGCTTTGCCACCCTCTCCGCTT hu 
PEBP2 AP2 Spl 
GCCTCCTCCCCTCCCTTCCCCGCCCTCCAGTACACTTGATCACTGAAGCCTCGAGCTGCG mo 
**** ******* * ** ********* * * * * ** * * * * * * * 
GCCTGGTCCCCTCTCCTCTCCGCCCTCCCGCTCGCCAGTCCATTTGATCAGCG-GAGACT hu 
SpT~ AP2
 v 
CGGCGGCTGGGGTGTCCCTGCGCCTCTCTTCCCCAGACCTGCGCGCTACTGCX5GCTCGGG mo 
******* *** * * * * * * * * * ********** ** ******* 
CGGCGGCCGGGCCG GGGCTICCCCGCAGC—CCCTGCGCGCTCCTAGAGCTCGGG hu 
NFKB A. 
CGGTCGCTCGCCTGGCTCTGCTCCATTTGACTGTCTGTGTGCAGTCGCAGAACTTCGAAG mo 
* ** ***** * ** **** * **** * ** * * ******** * **** ** 
CCGTGGCTCGTCGGGGTCTGTGTCTTTTGGC—TCCGAGGGCAGTCGCTGGGCTTCCGAG hu 
-114 AGGGTTTTGCGCTCCATCCGTGGCG-TTTCGCTTTTGTTCGGTTTTGTTGTTTATTTC-A mo 
**** ** * * * **** ****** *** 
-92 AGGGGGTTCGGGCCGCGTAGGGGCGC TTTGTTTTGTTCGG hu 
-56 TTTTTTTTTTTCCGGAGAGAG-GCGAGGCGGTGGTCCACACCCGCCCGAGGAGGAACATG 
**** ****** *** * * * ******** ** ** ***** *** **** 
-52 TTTTGITTTTTTGAGAGTGCGAGAGAGGCGGTCGTGCAGACCCG GGAGAAAG ATG hu 
Fig. 5. Sequence homology between the human and mouse p27Klpl promoters. A comparison of DNA sequence using GENETYX software 
was performed between the human (indicated as 'hu') and mouse (indicated as 'mo') promoters of the p27Klpl gene. The putative basal activity 
area from —774 to —435 is surrounded by the dotted line. The transcriptional start sites of the human (A.) and the mouse (v) p27Kipl genes 
are shown by the arrowheads. The consensus sites for various transcriptional factors are indicated and underlined. 
sites, and an ATF site (Fig. 5). Among these, two CTF and 
ATF sites are conserved, but other unknown conserved sites 
might be also important for the basal p27Klpl promoter activ-
ity. 
3.6. Future aspects of transcriptional regulation ofp27K'pl gene 
p27Klpl gene is known to be controlled by a post-transla-
tional mechanism such as ubiquitination [20] and by binding 
to El A oncoprotein [29]. However, several reports showed an 
increase of p27Klpl mRNA induced by vitamin D3 in U937 
cells [21] and by neuronal differentiation [22], and decrease in 
p27Klpl mRNA by anti-CD3 in T-lymphocytes [28], suggesting 
that the p27K]pl gene is also transcriptionally regulated in 
some cases. In addition, recent studies have shown the impor-
tance of the p27Klpl gene in the point of sensitization of tumor 
cells to an anti-cancer agent or cancer prognosis factor [30,18-
20]. Therefore, transcriptionally regulated agents of the 
p27Klpl gene may contribute to new strategies for the preven-
tion or therapy of malignancies which we have termed 'gene-
regulating chemoprevention or chemotherapy' [31]. Our study 
of the human p27Klpl promoter may provide information use-
ful for these strategies. 
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